Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris

Mango, D.; Ricci, S.; Manna, Pulak R.; Miggiano, Giacinto Abele Donato; Serra, Giovan Battista

doi:10.1016/0010-7824(96)00005-4

Cited by 48 publications

(15 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Earlier studies also failed to account for the substantial placebo effect that is typical of acne studies [21, 22]. In our study, we were able to put the therapeutic effect in perspective by measuring skin surface lipids and skin hydration.…”

Section: Discussionsupporting

confidence: 52%

Clinical Evidence of the Endocrinological Influence of a Triphasic Oral Contraceptive Containing Norgestimate and Ethinyl Estradiol in Treating Women with Acne vulgaris

2003

View full text Add to dashboard Cite

Background and Objective: The aim of this study was to evaluate the efficacy of a triphasic combination oral contraceptive (OC) containing norgestimate and ethinyl estradiol in the treatment of women with acne vulgaris. Methods: 12 female patients were included and 10 completed the trial. Over a period of 6 months, efficacy was assessed by means of facial acne lesion counts, by an investigator’s global assessment, by patients’ self-assessments and by measuring epidermal moisture and skin surface lipids. In addition, a photo documentation was compiled and hormone levels were measured. Results: After 6 months of therapy, the number of acne counts improved. The success of treatment was rated positively both by the investigator and by all patients but one who did not report any changes. Skin surface lipids were significantly reduced while skin hydration showed no significant change. Testosterone and progesterone decreased, and sex-hormone-binding globulin increased, significantly. Conclusion: Our data show that an OC containing norgestimate and ethinyl estradiol is a good therapeutic option for women of fertile age suffering from mild to moderate acne vulgaris.

show abstract

Section: Discussionsupporting

confidence: 52%

Clinical Evidence of the Endocrinological Influence of a Triphasic Oral Contraceptive Containing Norgestimate and Ethinyl Estradiol in Treating Women with Acne vulgaris

2003

View full text Add to dashboard Cite

show abstract

“…Oral contraceptives containing desogestrel have previously been shown to improve seborrhea 11 and acne [5][6][7][11][12][13] . The prevalence of seborrhea, in young women especially, makes it important to prescribe non-androgenic oral contraceptives that will not aggravate the skin or even induce acne.…”

Section: Discussionmentioning

confidence: 99%

“…Studies with a monophasic oral contraceptive containing 150 µg desogestrel and 30 µg ethinylestradiol have shown improvements in seborrhea 11 and acne 6,7,11,12 and that this preparation can be as effective as an oral contraceptive containing 2000 µg cyproterone acetate and 50 µg ethinylestradiol 5,13 . DSG-OC contains an ethinylestradiol dose similar to that of the monophasic desogestrel preparation, but with even less progestogen due to the phasic regimen.…”

mentioning

confidence: 96%

See 1 more Smart Citation

Effect of a desogestrel-containing oral contraceptive on the skin

Katz

Kempers

Akin

et al. 2000

The European Journal of Contraception & Reproductive Health

View full text Add to dashboard Cite

show abstract

“…For instance, with 2 pills containing 30 µg of ethinyl estradiol and a nonandrogenic progestin (75 µg of gestogen for one and 150 µg of desogestrel for the other), Mango et al [19] observed, after 9 months of treatment, a low score (absent or minimal), a decrease in biological hyperandrogenism and a normalization of echogenic ovarian texture. In a randomized placebo-controlled trial, Lucky et al [20] also evidenced the efficacy of a triphasic contraceptive containing 0.180, 0.215 and 0.250 mg of norgestimate and 35 µg of ethinyl estradiol.…”

Section: Hormonal Treatments May Be Beneficial For Acnementioning

confidence: 99%

Oral Contraceptives and Cyproterone Acetate in Female Acne Treatment

Beylot¹,

Doutre²,

Beylot‐Barry³

1998

Dermatology

View full text Add to dashboard Cite

The sebaceous gland is a target of androgens, and hormonal influences play an important role in the multifactorial pathogenesis of acne. In both men and women, acne may be related to an excessive hypersensitivity of the sebaceous end organ to androgens. However, in women, the ovarian and adrenal production and the plasma transport of androgens may be implicated, particularly in late-onset or persistent acne or with associated hirsutism. Many reports have shown that females with acne frequently have abnormal levels of circulating androgens. Hormonal treatment is not usually the first line in female acne. But in relation to the possibilities, particularly the tetracyclines, this may be a choice when one prescribes a pill like Dianette^® to a young woman presenting a mild acne and who requests contraception. However, antiandrogen treatment is sometimes mandatory, especially in resistant acne in adult women and/or in female acne which is resistant or relapsing rapidly after treatment with Roaccutane^® and which is often related to hyperandrogenism. Finally, in severe prepubertal acne, the possible cause is an adrenal enzymatic block of which the only treatment is hormonal.

show abstract

Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris

Cited by 48 publications

References 16 publications

Clinical Evidence of the Endocrinological Influence of a Triphasic Oral Contraceptive Containing Norgestimate and Ethinyl Estradiol in Treating Women with Acne vulgaris

Clinical Evidence of the Endocrinological Influence of a Triphasic Oral Contraceptive Containing Norgestimate and Ethinyl Estradiol in Treating Women with Acne vulgaris

Effect of a desogestrel-containing oral contraceptive on the skin

Oral Contraceptives and Cyproterone Acetate in Female Acne Treatment

Contact Info

Product

Resources

About